Skip to content
Open access

Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer

Aug 2026 · The Oncologist · Vol 31 · 0 citations · 46 references
Medicine

TL;DR

These findings support comprehensive genomic profiling to identify ALK fusions in CRC, which may inform the use of ALK-directed therapies, and highlight the frequent co-occurrence of MSI-high disease within this subgroup.

Abstract

Abstract Background Anaplastic lymphoma kinase (ALK) fusions are established oncogenic drivers and therapeutic targets in multiple malignancies, including non-small cell lung cancer, but are rare in colorectal cancer (CRC). Although ALK fusions in CRC have been associated with sensitivity to ALK inhibitors, their broader genomic context remains incompletely defined. We aimed to characterize the prevalence, clinicogenomic features, and therapeutic implications of ALK fusions in advanced CRC. Materials and Methods Comprehensive genomic profiling using hybrid capture-based next-generation sequencing was performed on 56 206 advanced CRC tumors to identify alterations, including ALK fusions. Microsatellite instability (MSI)/mismatch repair (MMR) status, tumor mutational burden (TMB), genomic ancestry, COSMIC trinucleotide signatures, and homologous recombination deficiency (HRD) signatures were derived from sequencing data. PD-L1 expression was assessed by immunohistochemistry. Results ALK fusions were identified in 63 tumors (0.1%). Compared with ALK fusion-negative CRC, ALK fusion-positive (ALKfus+) tumors demonstrated enrichment for MSI-high/MMR-deficient status and high TMB, with numerically higher PD-L1 expression. In contrast, canonical CRC driver alterations were markedly depleted, including KRAS, APC, and PIK3CA mutations. Conclusions ALK fusions define a rare but biologically distinct subset of CRC characterized by frequent MSI-high/MMR-deficient status and a unique genomic landscape. These findings support comprehensive genomic profiling to identify ALK fusions in CRC, which may inform the use of ALK-directed therapies, and highlight the frequent co-occurrence of MSI-high disease within this subgroup.

Read PDF

Similar papers

Open access Sep 2026

Genomic landscape of papillary thyroid carcinoma in Kuwait reveals novel candidate somatic variants

Targeted next-generation sequencing on 72 histologically confirmed PTC tumors collected between 2019 and 2022 broadened the candidate PTC mutational spectrum and emphasize the importance of genomic profiling in understudied populations.

R. Al-Awadhi, Materah Salem Alwehaidah, Tahani AlBaqer et al. · 0 citations
Open access Aug 2026

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer

The routine implementation of comprehensive genomic profiling in metastatic HER2-negative breast cancer, especially in metastatic HER2-negative breast cancer, is supported to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.

E. Papadopoulou, M. Stathoulopoulou, M. Matiatou et al. · 0 citations
Open access Aug 2026

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

It is proposed that MEK inhibitors may represent a relevant therapeutic option for BRAF fusions and non‐V600 BRAF mutant tumours, providing a novel strategy for this challenging disease.

Matilde Monti, Martina Brigida Romanello, L. Agnelli et al. · 0 citations
Open access Oct 2026

TP53 Genomic Alterations Including Targetable Y220C Mutation in Advanced Breast Cancer

TP53 Y220C is a rare genomic alteration (GA) with emerging targeted therapies. However, its prevalence in breast cancer remains undefined. We evaluated the prevalence of the Y220C alteration and association with other GAs. A total of 23,760 patients with advanced breast cancer were analyzed by hybrid ca...

N. Casasanta, Adriana M. Kahn, N. Fischbach et al. · 0 citations
Open access Sep 2026

KRAS Expression Complements Genomic Profiling in Identifying Therapeutic Vulnerability in Gastric Cancer.

BACKGROUND Gastric cancer (GC) remains a major therapeutic challenge. Although alterations in the RAS pathway occur in over 50% of tumors, only a limited proportion are clinically actionable. We investigated whether KRAS expression complements genomic profiling for patient stratification and therapeutic vulnerability i...

Yu-Lun Chen, Wei-Ching Chen, Ta-Sen Yeh et al. · 0 citations
Open access Sep 2026

Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC)

It is suggested that oncogene amplifications, rather than traditional genomic instability metrics, are associated with poor overall survival in MIBC, warranting validation in larger cohorts to assess their potential relevance as prognostic markers and therapeutic targets.

C. Poyet, A. S. Franzen, U. Bieri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.